ROCHESTER, NY – Vaccinex Inc., a clinical stage biotechnology company focused on the development of novel immune-based therapeutics has presented information regarding VX15/2503, the company’s leading therapeutic antibody program. Two posters were available for viewing at the 103rd annual American Association for Cancer Research (AACR) conference April 1st – 4th , 2012 in Chicago, IL. VX15/2503 antibody targets SEMA4D, a protein that experimental evidence has suggested is involved mechanistically in angiogenesis and tumor cell proliferation and invasion. In addition, SEMA4D has been linked experimentally to inflammation and demyelination of neurons. Neutralization of SEMA4D has been shown in experimental disease models to provide a neuroprotective effect which may ultimately benefit those who suffer from neurodegenerative diseases such as multiple sclerosis. Vaccinex has initiated a phase 1 clinical trial of VX15/2503 antibody in cancer patients and is actively planning a second phase 1 clinical trial in patients with multiple sclerosis. Links to pertinent presentations are provided below.

(AACR) - Nonclinical Safety and Pharmacology of VX15/2503
(AACR) - Reduction of In Vivo Tumor Growth and Angiogenesis

About Vaccinex, Inc.
Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of novel therapeutic antibodies. Utilizing its patented ActivMAb® antibody discovery technology, Vaccinex has developed the only library-based antibody discovery technology capable of directly expressing bivalent, fully human antibodies in mammalian cells. The company is building an impressive pipeline of therapeutic antibodies with the potential for effectively treating various autoimmune diseases and cancers. For additional information, please visit the company's website at www.vaccinex.com.